pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Velsipity
drug
save

etrasimod

Marketedupdated 4mo ago
by $PFE PFIZER INC
Approved
community read0 votes

indications

investigational
IBD (Crohn's + UC)

all catalysts(0)

nothing on the calendar yet

Trials studying etrasimod

  • phase2A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitisrecruitingn=36
  • phase1A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Womenrecruitingn=8
  • —A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitisrecruitingn=360
  • phase3An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitisactive not recruitingn=896
  • phase2Etrasimod as Prevention of Pouchitisnot yet recruitingn=40
  • phase2A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitisnot yet recruitingn=24
  • —An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitisnot yet recruitingn=553
  • phase2Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitiswithdrawn
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 12, 2028
~2.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (9)

  • Jun 21, 2036compositionUS 10301262
  • Jun 21, 2036method-of-use (U-3731)US 10676435
  • Jun 21, 2036compositionUS 11091435
  • Jun 21, 2036method-of-use (U-3731)US 11884626
  • Jan 6, 2036method-of-use (U-3730)US 11007175
  • Jan 6, 2036method-of-use (U-4047)US 12156866
  • Jan 6, 2036method-of-use (U-4255)US 12377071
  • Mar 5, 2030compositionUS 85808413.5y
  • Jul 22, 2029method-of-use (U-3732)US 91269322.9y

FDA exclusivities (1)

  • Oct 12, 2028NCENew Chemical Entity (5y)2.1y

News(0)

no news has mentioned this drug yet

brand
Velsipity
generic
etrasimod
indication
Ulcerative Colitis
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 8h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?